Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008

被引:10
作者
Arhin, Francis F. [1 ]
Moeck, Gregory [1 ]
Draghi, Deborah C. [2 ]
Pillar, Chris M. [2 ]
Sahm, Daniel F. [2 ]
机构
[1] Medicines Co, St Laurent, PQ H4S 2A1, Canada
[2] Eurofins Medinet, Chantilly, VA 20151 USA
关键词
D O I
10.1016/j.ijantimicag.2010.07.010
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
引用
收藏
页码:474 / 476
页数:3
相关论文
共 6 条
  • [1] Allen Norris E., 2010, Anti-Infective Agents in Medicinal Chemistry, V9, P23
  • [2] [Anonymous], 2009, M100S19 CLIN LAB STA
  • [3] Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
    Arhin, Francis F.
    Draghi, Deborah C.
    Pillar, Chris M.
    Parr, Thomas R., Jr.
    Moeck, Gregory
    Sahm, Daniel F.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (11) : 4762 - 4771
  • [4] CLINICAL LABORATORY STANDARDS INSTITUTE, 2009, M7A8 CLSI
  • [5] Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium
    McKay, Geoffrey A.
    Beaulieu, Sylvain
    Arhin, Francis F.
    Belley, Adam
    Sarmiento, Ingrid
    Parr, Thomas, Jr.
    Moeck, Gregory
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (06) : 1191 - 1199
  • [6] Management of multidrug-resistant organisms in health care settings, 2006
    Siegel, Jane D.
    Rhinehart, Emily
    Jackson, Marguerite
    Chiarello, Linda
    [J]. AMERICAN JOURNAL OF INFECTION CONTROL, 2007, 35 (10) : S165 - S193